A portfolio of extensively validated comprehensive profiling services to guide treatment and research decisions at optimal times beneficial to your patients' journeys
Foundation Medicine's portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions at optimal t imes beneficial to your patients' journeys:1-8
All of Foundation Medicine's services use our leading comprehensive genomic profiling approach, wich broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients' treatment options.1,2,4,5,7-13
As our understanding of cancer evolves, so do our tests
Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5
References
- Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol; 31: 1023–1031. 2013
- FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed August 2020).
- FoundationOne®CDx FDA Approval, 2017. Available at:
https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2020). - Data on file: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: http://www.eifu.online/FMI/190070862 (Accessed August 2020).
- Data on file: Clinical and analytical validation data file for FoundationOne Liquid CDx.
- FoundationOne Liquid CDx FDA Approval, 2020. Available at: https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2020).
- FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
- He J et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood; 127: 3004–3014. 2016
- Drilon A et al. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res ; 21: 3631–3639. 2015
- Rankin A et al. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist ; 21: 1306–1314. 2016
- Ross JS et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer; 122: 2654–2662. 2016
- Suh JH et al. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Oncologist ; 21: 684–691. 2016
- Hirshfield KM et al. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist; 21: 1315–1325. 2016
- Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed August 2020).